Benefits
Mild-moderate dementia (Villardita 1992 RCT positive)
Villardita 1992 (PMID 1603291) double-blind placebo-controlled parallel-group RCT in 60 outpatients with senile dementia of Alzheimer type (SDAT) and multi-infarct dementia (MID) of mild-to-moderate degree — oxiracetam 800 mg BID for 90 days. SIGNIFICANT IMPROVEMENTS in oxiracetam vs placebo on: Mini-Mental State Examination, Auditory Continuous Performance Test, Rey's 15 Words Test, Block Tapping Test, Mattis Word Fluency, Luria Alternating Series, Instrumental Activities of Daily Living. Open follow-up to 1 year showed maintained benefits. Among the most positive racetam dementia trials.
Alzheimer's disease (Green 1992 NEGATIVE counter-evidence)
Green 1992 double-blind placebo-controlled study in 24 carefully assessed patients with probable Alzheimer's disease — broad battery of neuropsychological tests showed NO improvement in oxiracetam-treated group OR in any individual treated patient. Authors concluded oxiracetam is INEFFECTIVE for AD-related cognitive impairment. Important counter-evidence to Villardita 1992. Honest interpretation: results inconsistent across populations and trial designs.
Vascular dementia / multi-infarct dementia
Some studies suggest oxiracetam may be more effective in vascular/multi-infarct dementia than pure Alzheimer's — possibly relating to microcirculation and metabolic effects. Mechanism plausible given hydroxylation enhances cerebral metabolic activity. Limited rigorous head-to-head comparison.
Craniocerebral injury (L-oxiracetam Phase 3 ongoing)
Phase 3 Chinese trial (NCT04205565) of L-oxiracetam injection for memory and cognitive impairment after craniocerebral injury — currently recruiting. L-isomer (active enantiomer) being developed by Nanjing Yoko Biomedical. Demonstrates ongoing scientific interest beyond original racemic oral formulation. Results pending.
Cognitive impairment after stroke (older evidence)
Some studies in post-stroke cognitive impairment showed oxiracetam improvements. Limited by older diagnostic criteria and modest sample sizes. Consistent with broader racetam class neuroprotective claims but not definitively established.
Mechanism of action
Cholinergic and glutamatergic enhancement
Oxiracetam increases ACh release and modulates AMPA/NMDA glutamatergic transmission. Cholinergic effects more pronounced than piracetam. Mechanism for cognitive enhancement claims via dual neurotransmitter system support.
Cerebral metabolic activity enhancement
Oxiracetam increases cerebral oxygen consumption, glucose utilization, and ATP/ADP ratio in brain — particularly in hypoxic conditions. Hydroxyl group may enhance this metabolic effect vs piracetam. Mechanism for proposed neuroprotective effects in vascular cognitive impairment.
Phosphoinositide turnover modulation
Oxiracetam stimulates phosphoinositide turnover and protein kinase C activation — second messenger pathways involved in synaptic plasticity and learning. Mechanism distinct from typical neurotransmitter modulation; may explain longer-duration cognitive effects.
BBB penetration via active transport
Crosses BBB efficiently despite water-solubility — possibly via active transport. CNS bioavailability higher than expected for compound's polarity. Half-life longer than piracetam (8-10 hours) — longer cognitive effect duration.
Clinical trials
Double-blind placebo-controlled parallel-group RCT (Villardita C, Grioli S, Lomeo C, Cattaneo C, Parini J 1992, Neuropsychobiology 25(1):24-28, doi:10.1159/000118805, PMID 1603291).
60 male and female outpatients with SDAT (Alzheimer type) and multi-infarct dementia (MID) of mild-moderate degree. Oxiracetam 800 mg BID (1600 mg/day) vs placebo for 90 days. Open follow-up to 1 year for oxiracetam group.
SIGNIFICANT IMPROVEMENTS in oxiracetam group vs placebo on: MMSE, Auditory Continuous Performance Test, Rey's 15 Words Test, Block Tapping Test, Mattis Word Fluency, Luria Alternating Series, Instrumental ADL. Open follow-up 1 year: 29 of 30 patients continued; benefits maintained. POSITIVE RCT — among more robust racetam dementia trials. Limited by older diagnostic criteria and modest sample.
Double-blind placebo-controlled treatment study (Green RC, Goldstein FC, Auchus AP, Presley R, Clark WS, Van Tuyl L, Green J, Hersch SM, Karp HR 1992, Arch Neurol 49(11):1135-1136, doi:10.1001/archneur.1992.00530350049019, PMID 1444879). JAMA Neurology.
24 carefully assessed patients with probable Alzheimer's disease. Broad battery of neuropsychological tests applied.
OXIRACETAM INEFFECTIVE in reducing cognitive impairment due to Alzheimer's disease. Broad battery of neuropsychological tests FAILED to reveal any improvement in treated group OR in any individual treated patient when individual scores analyzed. NEGATIVE RCT — important counter-evidence to Villardita 1992. Honest interpretation: oxiracetam efficacy varies across study designs, populations, and assessment methods. Conservative conclusion: weak overall efficacy for AD specifically.
Phase 3 randomized double-blind positive drug/placebo parallel-controlled multicenter trial (NCT04205565, Nanjing Yoko Biomedical sponsor).
Patients with mild-to-moderate craniocerebral injury (GCS 10-15) for memory and cognitive impairment. L-oxiracetam injection (active enantiomer) vs racemic oxiracetam injection vs placebo, IV daily.
Currently RECRUITING. Demonstrates ongoing pharmaceutical interest in L-isomer development for IV use in TBI cognitive impairment. Will provide rigorous Phase 3 evidence for specific TBI cognition indication. Results pending. May represent revival of oxiracetam research with chiral selectivity and IV bioavailability.